Microbicide Science
Overview
The HPTN's microbicide agenda has transitioned to the Microbicide Trials Network (MTN). The information provided below describes the research that was conducted by the HPTN prior to that transition.
Microbicides are antimicrobial products formulated for application to the surface of the vagina and/or rectum for the prevention of HIV transmission during sexual intercourse. They are considered to be one of the most promising preventive interventions to emerge over the past decade. Even a partially effective microbicide might have a profound impact on the dynamics of HIV transmission. Researchers have developed a mathematical model that shows that if even a small proportion of women in lower income countries used a 60% efficacious microbicide in half the sexual encounters where condoms are not used, 2.5 million HIV infections could be averted over a 3 year period.
HPTN Microbicide Studies
|
Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel |
(Concluded) | |
|
Characterization of Baseline Mucosal Indices of Injury and Inflammation in Men for Use in Rectal Microbicide Trials |
(Concluded) | |
|
HIV Prevention Preparedness Study |
(Concluded) | |
|
Phase I Safety and Acceptability Study of the Vaginal Microbicide Agent PMPA Gel |
(Concluded) | |
|
Phase I Safety and Acceptability Study of the Vaginal Microbicide 6% Cellulose Sulfate Gel Among HIV-Infected Women |
(Concluded) | |
|
A Phase I Safety and Acceptability Study of the Investigational Vaginal Microbicide PRO 2000/5 Gel (P) |
(Concluded) | |
|
Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO2000/5 Gel (P) for the Prevention of HIV Infection in Women |
(Concluded) | |
|
Male Tolerance Study of BufferGel and PRO 2000/5 Gel (P) |
(Concluded) | |
|
Condom Promotion and Counseling Study |
(Concluded) |
